Johnson & Johnson culls $1.6B argenx blood cancer drug collab

Johnson & Johnson is walking away from a $1.6 billion biobucks blood cancer med deal with Belgium’s argenx for the CD70-targeting cusatuzumab.

The pair first teamed up for the med, an anti-CD70 SIMPLE antibody, across a range of blood cancers and disorders including acute myeloid leukemia, myelodysplastic syndrome and other hematological malignancies back in 2018.